GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis (REVISE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
W.L.Gore & Associates
ClinicalTrials.gov Identifier:
NCT00737672
First received: August 15, 2008
Last updated: October 14, 2014
Last verified: October 2014
Results First Received: February 6, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Renal Failure
Hemodialysis
Interventions: Device: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface
Procedure: Percutaneous Transluminal Angioplasty

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
VIABAHN Treatment Group

Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm

GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface: Deployment of investigational stent graft at the venous anastomosis

PTA Treatment Group

Percutaneous Transluminal Angioplasty (PTA)in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm

Percutaneous Transluminal Angioplasty: Percutaneous Transluminal Angioplasty at the venous anastomosis


Participant Flow:   Overall Study
    VIABAHN Treatment Group     PTA Treatment Group  
STARTED     145     148  
Exclusions Due to Protocol Deviations     14     10  
Per Protocol Population     131     138  
COMPLETED     65     65  
NOT COMPLETED     80     83  
Graft Abandonment                 48                 56  
Death                 23                 22  
Withdrawal by Subject                 1                 2  
Lost to Follow-up                 1                 0  
Miscellaneous                 7                 1  
Physician Decision                 0                 2  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
VIABAHN Treatment Group

Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm.

GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface: Deployment of investigational stent graft at the venous anastomosis.

PTA Treatment Group

Percutaneous Transluminal Angioplasty (PTA) in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm.

Percutaneous Transluminal Angioplasty: Percutaneous Transluminal Angioplasty at the venous anastomosis.

Total Total of all reporting groups

Baseline Measures
    VIABAHN Treatment Group     PTA Treatment Group     Total  
Number of Participants  
[units: participants]
  145     148     293  
Age  
[units: Years]
Mean ± Standard Deviation
  62.2  ± 12.9     61.3  ± 15.0     61.7  ± 14.0  
Gender  
[units: Participants]
     
Female     76     75     151  
Male     69     73     142  
Ethnicity (NIH/OMB)  
[units: Participants]
     
Hispanic or Latino     16     30     46  
Not Hispanic or Latino     126     114     240  
Unknown or Not Reported     3     4     7  
Race (NIH/OMB)  
[units: Participants]
     
American Indian or Alaska Native     0     1     1  
Asian     9     7     16  
Native Hawaiian or Other Pacific Islander     1     0     1  
Black or African American     74     80     154  
White     61     56     117  
More than one race     0     0     0  
Unknown or Not Reported     0     4     4  
Region of Enrollment  
[units: Participants]
     
United States     145     148     293  
Body Mass Index  
[units: Kg/m^2]
Mean ± Standard Deviation
  29.7  ± 9.1     29.5  ± 8.6     29.6  ± 8.8  
History of Diabetes  
[units: Participants]
     
History of Diabetes = YES     94     98     192  
History of Diabetes = NO     51     50     101  
History of Hypertension  
[units: Participants]
     
History of Hypertension = YES     143     144     287  
History of Hypertension = NO     2     4     6  
Age of Vascular Access Graft  
[units: Years]
Mean ± Standard Deviation
  1.93  ± 1.92     2.28  ± 2.64     2.11  ± 2.31  
Total Number of Prior Interventions at the Target Lesions  
[units: Number of Prior Interventions]
Mean ± Standard Deviation
  1.85  ± 2.20     1.81  ± 2.34     1.83  ± 2.27  
Total Number of Prior Interventions to the Current Prosthetic Graft or Circuit  
[units: Number of Prior Interventions]
Mean ± Standard Deviation
  2.28  ± 2.75     2.26  ± 2.90     2.27  ± 2.82  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Target Lesion Primary Patency at 6 Months   [ Time Frame: 6 months ]

2.  Primary:   Target Lesion Primary Patency at 12 Months   [ Time Frame: 12 Months ]

3.  Primary:   Target Lesion Primary Patency at 24 Months   [ Time Frame: 24 Months ]

4.  Primary:   Freedom From Major Device, Procedure and Treatment Site-related Adverse Adverse Events Through 30 Days Post-procedure   [ Time Frame: 30 days ]

5.  Secondary:   Assisted Primary Patency at 6 Months   [ Time Frame: 6 months ]

6.  Secondary:   Assisted Primary Patency at 12 Months   [ Time Frame: 12 months ]

7.  Secondary:   Assisted Primary Patency at 24 Months   [ Time Frame: 24 months ]

8.  Secondary:   Access Secondary Patency at 6 Months   [ Time Frame: 6 months ]

9.  Secondary:   Access Secondary Patency [12 Months] Units Percentage of Subjects   [ Time Frame: 12 months ]

10.  Secondary:   Access Secondary Patency [24 Months] Units Percentage of Subjects   [ Time Frame: 24 months ]

11.  Secondary:   Circuit Primary Patency   [ Time Frame: 6 months ]

12.  Secondary:   Circuit Primary Patency [12 Months] Units Percentage of Subjects   [ Time Frame: 12months ]

13.  Secondary:   Circuit Primary Patency [24 Months] Units Percentage of Subjects   [ Time Frame: 24 months ]

14.  Secondary:   Clinical Success   [ Time Frame: Following Index Procedure ]

15.  Secondary:   Anatomic Success   [ Time Frame: Index Procedure ]

16.  Secondary:   Procedural Success   [ Time Frame: Following Index Procedure ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Clinical Project Manager
Organization: W.L. Gore and Associates, Inc.
phone: 928-864-3771
e-mail: cavery@wlgore.com


No publications provided


Responsible Party: W.L.Gore & Associates
ClinicalTrials.gov Identifier: NCT00737672     History of Changes
Other Study ID Numbers: AVR 06-01, G070069
Study First Received: August 15, 2008
Results First Received: February 6, 2014
Last Updated: October 14, 2014
Health Authority: United States: Food and Drug Administration